CN1906170A - 用作抗精神病药的7－[4－(4－氯苄氧基)苯磺酰基]－8－甲氧基－3－甲基－2,3,4,5－四氢－1h－3－苯并氮杂䓬鎓马来酸盐或甲苯磺酸盐 - Google Patents

用作抗精神病药的7－[4－(4－氯苄氧基)苯磺酰基]－8－甲氧基－3－甲基－2,3,4,5－四氢－1h－3－苯并氮杂䓬鎓马来酸盐或甲苯磺酸盐 Download PDF

Info

Publication number
CN1906170A
CN1906170A CNA2004800410778A CN200480041077A CN1906170A CN 1906170 A CN1906170 A CN 1906170A CN A2004800410778 A CNA2004800410778 A CN A2004800410778A CN 200480041077 A CN200480041077 A CN 200480041077A CN 1906170 A CN1906170 A CN 1906170A
Authority
CN
China
Prior art keywords
methyl
benzenesulfonyl
benzazepine
tetrahydrochysene
maleate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800410778A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·克拉彭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1906170A publication Critical patent/CN1906170A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNA2004800410778A 2003-11-28 2004-11-25 用作抗精神病药的7－[4－(4－氯苄氧基)苯磺酰基]－8－甲氧基－3－甲基－2,3,4,5－四氢－1h－3－苯并氮杂䓬鎓马来酸盐或甲苯磺酸盐 Pending CN1906170A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0327740.7 2003-11-28
GBGB0327740.7A GB0327740D0 (en) 2003-11-28 2003-11-28 Novel compounds

Publications (1)

Publication Number Publication Date
CN1906170A true CN1906170A (zh) 2007-01-31

Family

ID=29798028

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800410778A Pending CN1906170A (zh) 2003-11-28 2004-11-25 用作抗精神病药的7－[4－(4－氯苄氧基)苯磺酰基]－8－甲氧基－3－甲基－2,3,4,5－四氢－1h－3－苯并氮杂䓬鎓马来酸盐或甲苯磺酸盐

Country Status (18)

Country Link
US (1) US20070275948A1 (https=)
EP (1) EP1687279A1 (https=)
JP (1) JP2007512285A (https=)
KR (1) KR20060103322A (https=)
CN (1) CN1906170A (https=)
AR (1) AR046719A1 (https=)
AU (1) AU2004293179A1 (https=)
BR (1) BRPI0417029A (https=)
CA (1) CA2547444A1 (https=)
GB (1) GB0327740D0 (https=)
IL (1) IL175663A0 (https=)
IS (1) IS8500A (https=)
MA (1) MA28177A1 (https=)
NO (1) NO20062970L (https=)
RU (1) RU2006122959A (https=)
TW (1) TW200528433A (https=)
WO (1) WO2005051916A1 (https=)
ZA (1) ZA200603781B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115998724A (zh) * 2023-03-28 2023-04-25 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510599D0 (en) * 2005-05-24 2005-06-29 Glaxo Group Ltd Novel compounds
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
JP5989965B2 (ja) * 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
CA2970502A1 (en) * 2014-12-12 2016-06-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
US11225487B2 (en) 2017-02-17 2022-01-18 Trevena, Inc. 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same
US20210347758A1 (en) 2018-10-03 2021-11-11 Tesaro, Inc. Crystalline Forms of Niraparib Freebase
JP2023546729A (ja) * 2020-10-27 2023-11-07 トレベナ・インコーポレイテッド デルタオピオイドモジュレーターの結晶形及び非晶形

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518414A (ja) * 2001-12-21 2005-06-23 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー ドーパミン受容体のモジュレーターとしての７−スルホニル−３−ベンゾアゼピン誘導体およびｃｎｓ障害の治療のためのその使用
KR20040081201A (ko) * 2002-02-13 2004-09-20 글락소 그룹 리미티드 항정신병제로서 벤젠술폰아미드 유도체
AR040126A1 (es) * 2002-05-29 2005-03-16 Glaxo Group Ltd Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115998724A (zh) * 2023-03-28 2023-04-25 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Also Published As

Publication number Publication date
US20070275948A1 (en) 2007-11-29
JP2007512285A (ja) 2007-05-17
KR20060103322A (ko) 2006-09-28
AR046719A1 (es) 2005-12-21
RU2006122959A (ru) 2008-01-10
ZA200603781B (en) 2007-09-26
BRPI0417029A (pt) 2007-02-06
IL175663A0 (en) 2006-09-05
AU2004293179A1 (en) 2005-06-09
MA28177A1 (fr) 2006-09-01
WO2005051916A1 (en) 2005-06-09
IS8500A (is) 2006-06-08
TW200528433A (en) 2005-09-01
NO20062970L (no) 2006-08-21
EP1687279A1 (en) 2006-08-09
GB0327740D0 (en) 2003-12-31
CA2547444A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
US8481566B2 (en) Compounds which have activity at M1 receptor and their uses in medicine
US8299257B2 (en) Compounds which have activity at M1receptor and their uses in medicine
IL208575A (en) Active indoles as modulators of the alpha-7 acetylcholine nicotine receptor subunit, pharmacological preparations including them and their use in the manufacture of drugs to treat psychotic disorders
EP2265582B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
US8288412B2 (en) Compounds which have activity at M1 receptor and their uses in medicine
EP2294068B1 (fr) DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE
CN1906170A (zh) 用作抗精神病药的7－[4－(4－氯苄氧基)苯磺酰基]－8－甲氧基－3－甲基－2,3,4,5－四氢－1h－3－苯并氮杂䓬鎓马来酸盐或甲苯磺酸盐
TW200901979A (en) Compounds which have activity at M1receptor and their uses in medicine
US8426443B2 (en) Compounds which have activity at M1 receptor and their uses in medicine
EP2344483B1 (en) Compounds which have activity at m1 receptor and their uses in medicine
US20090163475A1 (en) Crystalline form of benzazepinium maleate derivative
US8344000B2 (en) Compounds which have activity at M1 receptor and their uses in medicine
US20070225276A1 (en) 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents
MXPA06006077A (en) 7-[4-(4 -chlorobenzyloxy) benzenesulfonyl]-8-methoxy -3-methyl-2, 3, 4, 5-tetrahydro -1h-3- benzazepinium maleate or tosylate as antipsychotics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication